Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.46 USD
-0.31 (-3.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
TERN 7.46 -0.31(-3.99%)
Will TERN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TERN
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice
Other News for TERN
3 Biotech Stocks That Could Have Investors Grinning Soon
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Terns Pharmaceuticals (TERN) and Stryker (SYK)
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition